Stockscreener 앱 받기
8.05
1.11%
-0.09
시간 외 거래:
8.06
0.010
+0.12%
Novavax Inc 주식(NVAX)의 최신 뉴스
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
(NVAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors - webull.com
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
NVAX Stock Is Rising Even After A Revenue Collapse – Here’s The Catch - Stocktwits
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX - MarketBeat
Novavax, Inc. (NVAX) Stock Analysis: Growth Potential Amidst A 77% Upside - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Options Chain - Yahoo! Finance Canada
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research - MarketBeat
Novavax (NVAX) Gets a Sell from Bank of America Securities - The Globe and Mail
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX - MarketBeat
Novavax (NVAX) Stock Faces Revenue Slump As Losses Deepen - Sahm
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised - Yahoo Finance
State Street Corporation (NYSE: STT) discloses 7.1% ownership of Novavax - Stock Titan
Novavax, Inc. Stock 12‑Month Price Target Cut to $13.75, Implies 78% Upside - TradingView
Novavax Q2 2026 slides: partnership pivot drives revenue beat By Investing.com - Investing.com Nigeria
NVAX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Novavax Q2 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
NVAX Looks 107.0% Overvalued on GF Value™ - GuruFocus
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M - GuruFocus
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ... - Yahoo Finance
Novavax Q2 2026 Earnings Call Transcript - MarketBeat
Novavax, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-08-06 - Seeking Alpha
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals - Yahoo Finance
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand - kfgo.com
Novavax Q2 2026 slides: partnership pivot drives revenue beat - Investing.com
Novavax Raises 2026 Revenue Outlook After Q2 Earnings Beat - citybiz
NVAX: Q2 2026 revenue reached $57M, with strong Matrix-M growth and major partnership milestones ahead - TradingView
Earnings call transcript: Novavax beats Q2 2026 estimates, lifts revenue outlook - Investing.com
Is Novavax Inc (NVAX) Under Pressure After Q2 Earnings Miss? EPS - GuruFocus
Novavax, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses - Yahoo Finance
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Are Medical Stocks Lagging Novavax (NVAX) This Year? - Yahoo Finance
NVAX: Q2 2026 product sales rose 76% YoY, but total revenue fell sharply as milestone payments declined - TradingView
Novavax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings Flash (NVAX) Novavax Posts Q2 Net Loss of $0.32 a Share, vs. FactSet Est. of $0.38 Loss - marketscreener.com
Novavax (NASDAQ:NVAX) Exceeds Q2 CY2026 Expectations - Yahoo Finance
Novavax raises 2026 outlook after Q2 beat (NVAX:NASDAQ) - Seeking Alpha
NOVAVAX INC NOVAVAX ORD SHS (0A3S.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Novavax lifts annual revenue forecast as licensing bets offset weak vaccine demand - WTVB
Novavax reports Q2 2026 revenue $57M, narrows R&D+SG&A guidance and raises 2026 revenue framework - TradingView
Novavax Q2 Revenue Falls 76 Percent to $57 Million - Quiver Quantitative
Novavax: Q2 Earnings Snapshot - Yahoo Finance
Novavax (Nasdaq: NVAX) Q2 revenue $57M, swings to $53M loss - Stock Titan
NVAX: Q2 2026 revenue dropped 76% year-over-year, but product sales and Sanofi milestones advanced - TradingView
Earnings Flash (NVAX) Novavax, Inc. Reports Q2 Revenue $56.7M, Vs. FactSet Est of $52.5M - moomoo.com
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights - PR Newswire
NVAX: Q2 2026 saw a revenue drop and net loss, but strong liquidity and major milestones remain ahead - TradingView
NOVAVAX INC 2Q 2026: Revenue $56.7M, EPS ($0.32) — 10-Q Summary - TradingView
Novavax, Inc. (Nasdaq: NVAX) swings to Q2 loss on lower sales - Stock Titan
Novavax earnings up next: Can partnerships offset vaccine slump? - Investing.com
Novavax earnings up next: Can partnerships offset vaccine slump? By Investing.com - Investing.com Nigeria
NVAX Q2'26 Earnings: EPS estimate is (0.38) USD - TradingView
Novavax Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Novavax, Inc. (NVAX) Stock Analysis: Is A 90% Upside Potential Worth The Risk? - DirectorsTalk Interviews
0.52%
0.07%
자본화:
|
볼륨(24시간):